S09 Stock Overview
Operates as a clinical-stage oncology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sutro Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.38 |
| 52 Week High | US$5.45 |
| 52 Week Low | US$2.04 |
| Beta | 1.17 |
| 11 Month Change | -23.23% |
| 3 Month Change | -45.41% |
| 1 Year Change | 7.21% |
| 33 Year Change | -83.24% |
| 5 Year Change | -76.08% |
| Change since IPO | -80.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| S09 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.9% | -0.7% | 0.2% |
| 1Y | 7.2% | -17.2% | 8.5% |
Return vs Industry: S09 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: S09 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| S09 volatility | |
|---|---|
| S09 Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: S09's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: S09's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 306 | Bill Newell | www.sutrobio.com |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Sutro Biopharma, Inc. Fundamentals Summary
| S09 fundamental statistics | |
|---|---|
| Market cap | €198.75m |
| Earnings (TTM) | -€119.03m |
| Revenue (TTM) | €154.57m |
1.3x
P/S Ratio-1.7x
P/E RatioIs S09 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S09 income statement (TTM) | |
|---|---|
| Revenue | US$160.96m |
| Cost of Revenue | US$234.77m |
| Gross Profit | -US$73.82m |
| Other Expenses | US$50.14m |
| Earnings | -US$123.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | -45.86% |
| Net Profit Margin | -77.01% |
| Debt/Equity Ratio | 0% |
How did S09 perform over the long term?
See historical performance and comparison